Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation

摘要: PD-1 immune checkpoint blockade occasionally results in durable clinical responses advanced metastatic cancers. However, mechanism-based predictors of response to this immunotherapy remain incompletely characterized. We performed comprehensive genomic profiling on a tumor and germline sample from patient with refractory lung adenocarcinoma who achieved marked long-term benefit anti-PD-L1 therapy. discovered activating somatic amino acid variants JAK3 that promoted PD-L1 induction cancer cells the microenvironment. These findings suggest alterations deregulate cytokine receptor signal transduction could contribute activation engagement cancer.